Angina drug reduces deaths in heart failure

Katwala, Amit
September 2010
GP: General Practitioner;9/3/2010, p8
The article presents information on the findings of two studies on cardiology. The studies states that reducing heart rate with ivabradine can reduce the risk of cardiovascular death in heart failure patients. The first study investigated that effects of ivabradine in 6,505 patients with chronic heart failure.


Related Articles

  • Limited role for ivabradine in the treatment of chronic heart failure. Cullington, Damien; Goode, Kevin M.; Cleland, John G. F.; Clark, Andrew L. // Heart;Dec2011, Vol. 97 Issue 23, p1961 

    Objective: To quantify the proportion of patients attending a community heart failure clinic with left ventricular systolic impairment who might be suitable for ivabradine therapy. Background: High resting heart rate is an important and potentially modifiable risk factor in patients with heart...

  • Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Juenger, J.; Schellberg, D.; Kroemer, S.; Haunstetter, A.; Zugck, C.; Herzog, W.; Hoass, M. // Heart;Mar2002, Vol. 87 Issue 3, p235 

    Objective: To assess health related quality of life of patients with congestive heart failure; to compare their quality of life with the previously characterised general population and in those with other chronic diseases; and to correlate the different aspects of quality of life with relevant...

  • Exercise in Chronic Heart Failure Improves Survival. Walling, Anne D. // American Family Physician;9/15/2004, Vol. 70 Issue 6, p1153 

    Discusses the study "Exercise Training Meta-Analysis of Trials in Patients With Chronic Heart Failure," published in the January 24, 2004 issue of the "British Medical Journal." Study subjects and procedures; Findings; Conclusion.

  • Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study. Maison, Patrick; Cunin, Patrick; Hemery, François; Fric, Florence; Elie, Nicole; Del'Volgo, Aldo; Dubois-Randé, Jean; Hittinger, Luc; Macquin-Mavier, Isabelle // European Journal of Clinical Pharmacology;Jul2005, Vol. 61 Issue 5/6, p445 

    Objectives: Trials in chronic heart failure (CHF) include few patients older than 75 years, who represent a large proportion of CHF patients. We evaluated the influence of age on CHF-medication use and of CHF medications on hospitalisation in patients older than 75 years. Methods: Included in...

  • THESUS-HF study reveals acute AF trends in Africa.  // Cardiology Today;Oct2012, Vol. 15 Issue 10, p39 

    The article focuses on a study of patients at 12 hospitals in nine African countries which revealed that acute heart failure (HF) has a predominantly nonischemic cause in African patients.

  • Heart failure.  // Pulse;May2013, p62 

    A review is offered of a drug advertisement for Procoralan for chronic heart failure.

  • Ventilação não Invasiva por Dois Níveis de Pressão é Efetiva na Insuficiência Cardíaca Crónica Agudizada. Schafascheck, Edilete; Campos, Renata; Tibola, Juliano // Revista Inspirar Movimento & Saude;jan/fev2012, Vol. 4 Issue 1, p38 

    Heart failure is a systemic syndrome, which causes inadequate blood supply to tissue metabolic needs. In addition, there is an interaction with the lung, causing cardio-pulmonary failure. The noninvasive mechanical ventilation (NIMV) has been used as a supportive therapy in patients with cardiac...

  • Global Insights.  // Health Affairs;Jan/Feb2009, Vol. 28 Issue 1, p178 

    The article discusses various reports published within the issue, including one by Chris Ham on the origins, organization and results of efforts in managing chronic diseases in Great Britain, and another by Julie Sochalski and colleagues on the examination of studies in the management of heart...

  • Heart failure care checklist.  // Southern Illinois Labor Tribune;6/21/2012, Vol. 75 Issue 46, p10 

    The article focuses on guidelines issued by Kapil Parakh, director of the Johns Hopkins Bayview Comprehensive Heart Failure Program for heart patients which include monitoring one's weight daily, watching for sigsn of heart failure and reducing intake of sodium.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics